๐๐ฉ๐ข๐ง๐๐ฅ ๐๐จ๐ซ๐ ๐๐ง๐ฃ๐ฎ๐ซ๐ฒ ๐๐ง๐ฏ๐๐ฌ๐ญ๐จ๐ซ ๐๐ฒ๐ฆ๐ฉ๐จ๐ฌ๐ข๐ฎ๐ฆ: Axonis Therapeutics' CEO Joanna Stanicka discusses the importance of KCC2 inhibition in CNS disorders. She describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that KCC2 inhibition plays in neuronal function. Full video: https://lnkd.in/gCcbGZxM BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
GREAT job, Joanna !!! Keep going !
Great insights, Joanna Stanicka! Well done.
Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.
1wFascinating insights from Joanna Stanicka at Axonis Therapeutics on KCC2 inhibition in CNS disorders! It's exciting to see advancements in restoring neuronal function with innovative small molecules. Looking forward to learning more about Axonis' progress in this critical area. ๐ง ๐ #Biotech #CNSDisorders